Polygenic scores (PGSs) have emerged as promising tools for complex trait risk prediction.
The application of these scores to pharmacogenomics provides new opportunities to …

Adverse drug reactions involving the skin are commonly known as drug eruptions. Severe
drug eruption may cause severe cutaneous adverse drug reactions (SCARs), which are …

Only a small fraction of early drug programs progress to the market, due to safety and
efficacy failures, despite extensive efforts to predict safety. Characterizing the effect of …

Drug development is a costly, time-consuming, and challenging endeavour, with only a few
agents reaching the threshold of approval for clinical use. Therefore, approaches to more …

Introduction: Drug-induced liver injury (DILI) is a severe adverse drug reaction which is of
major concern to patients, clinicians and the pharmaceutical industry. Accurate and rapid …

The application of pharmacogenomics could meaningfully contribute toward medicines
optimization within primary care. This review identified 13 studies describing eight …

Adverse drug reactions (ADRs) are an important cause of morbidity and mortality. Genetic
factors predispose to many ADRs, affecting susceptibility to both type A and type B reactions …

We developed a panel-based NGS pipeline for comprehensive analysis of 340 genes
involved in absorption, distribution, metabolism and excretion (ADME) of drugs, other …

Human leukocyte antigen (HLA) is a hallmark genetic marker for the prediction of certain
immune-mediated adverse drug reactions (ADRs). Numerous basic and clinical research …

Drug-induced liver injury (DILI) is one of the serious adverse drug reactions (ADRs), which
belongs to immune-mediated adverse drug reactions (IM-ADRs). As an essential health …